Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

The Role of Direct Oral Anticoagulant in Patients with Acute Coronary Syndrome on Single or Dual Antiplatelet Regime: Review of Opportunities and Challenges

Author(s): Asim A. Elnour*, András Komócsi, Péter Kupó, Israa Y. El Khidir, Seeba Zachariah, Kishore G. Sam, Sahar Asim and Adel Sadeq

Volume 16, Issue 1, 2021

Published on: 18 May, 2020

Page: [52 - 63] Pages: 12

DOI: 10.2174/1574884715666200518091359

Price: $65

Abstract

Background: Despite the developments of single or dual antiplatelet therapy consisting of aspirin and/or clopidogrel, prasugrel or ticagrelor, post-acute coronary syndrome a room for potential improvement towards optimal prevention persist. The addition of a direct oral anticoagulant to the antiplatelet treatment of patients with the acute coronary syndrome is clinically practiced in cases where anticoagulation is indicated by high thromboembolic risk.

Objective: The main objective of this review was to explore the role of supplementation with a direct oral anticoagulant to antiplatelet (aspirin or P2Y12 inhibitor) in patients with the acute coronary syndrome.

Methods: We have searched the Medline for studies involving direct oral anticoagulant use in acute coronary syndrome. We have reviewed specific relevant 9 meta-analyses between the years 2012 to 2019.

Results: Our review of nine meta-analyses has revealed that the addition of direct oral anticoagulant to antiplatelet therapy compared with antiplatelet alone was beneficial about the composite endpoints of major ischemic events in patients with the acute coronary syndrome. Furthermore, the combined regimen of single antiplatelet plus direct oral anticoagulant is as effective as the triple regimen of dual antiplatelet plus direct oral anticoagulant and results in less bleeding.

Conclusion: Cardiologists should balance the efficacy with a higher risk of bleeding with more intensified DOAC therapy. Better risk characterization and timely adaptation of the regime to the patient's need should be tested. Recurrent ischemic events and bleeding event risk scoring should guide individualized treatment.

Keywords: Acute coronary syndrome ACS, dual antiplatelet therapy DAPT, direct oral anticoagulant DOAC, single antiplatelet therapy SAPT, therapeutic versatility, anticoagulants.

« Previous Next »
Graphical Abstract

[1]
Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R. Mortality from ischemic heart disease: Analysis of data from the world health organization and coronary artery disease risk factors from ncd risk factor collaboration. Circ Cardiovasc Qual Outcomes 201912(6)e005375
[2]
Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015; 12(1): 30-47.
[http://dx.doi.org/10.1038/nrcardio.2014.156] [PMID: 25286881]
[3]
Product Information: XARELTO(R) oral tablets, rivaroxaban oral tablets. Janssen Pharmaceuticals Inc (per manufacturer). 2019.http://www.janssenlabels.com/package-insert/product-monograph/prescribing information/XAR -ELTO-pi.pdf [2019];
[4]
January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64(21): 2246-80.
[http://dx.doi.org/10.1016/j.jacc.2014.03.021] [PMID: 24685669]
[5]
Lip GY, Windecker S, Huber K, et al. Document Reviewers. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: A joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35(45): 3155-79.
[http://dx.doi.org/10.1093/eurheartj/ehu298] [PMID: 25154388]
[6]
Micromedex. https://www.micromedexsolutions.com [December 10th, 2020.];
[7]
Product Information: BRILINTA(TM) oral tablets, ticagrelor oral tablets. AstraZeneca LP (per manufacturer). 2011.https://accessdata.fda.gov/drugsatfda_docs/label/2016/0 22433s0201b1.pdf [Accessed December 15th, 2019.];
[8]
Product Information: BRILINTA(R) oral tablets, ticagrelor oral tablets. AstraZeneca (per Manufacturer) 2015 [Accessed December 15th, 2019.];.
[9]
Washam JB, Dolor RJ, Jones WS, et al. Dual antiplatelet therapy with or without oral anticoagulation in the postdischarge management of acute coronary syndrome patients with an indication for long term anticoagulation: A systematic review. J Thromb Thrombolysis 2014; 38(3): 285-98.
[http://dx.doi.org/10.1007/s11239-014-1094-1] [PMID: 24891133]
[10]
Shin D, Mohanty BD, Lee ES. Dual versus triple antithrombotic therapy after percutaneous coronary intervention or acute coronary syndrome in patients with indication for anticoagulation: an updated meta-analysis. Coron Artery Dis 2018; 29(8): 670-80.
[http://dx.doi.org/10.1097/MCA.0000000000000660] [PMID: 30222595]
[11]
Briasoulis A, Papageorgiou N, Zacharia E, et al. Meta-analysis of oral anticoagulants with dual versus single antiplatelet therapy in patients after percutaneous coronary intervention. Am J Cardiovasc Drugs 2016; 16(2): 103-10.
[http://dx.doi.org/10.1007/s40256-015-0154-z] [PMID: 26650924]
[12]
Dézsi CA, Dézsi BB, Dézsi AD. Management of dental patients receiving antiplatelet therapy or chronic oral anticoagulation: A review of the latest evidence. Eur J Gen Pract 2017; 23(1): 196-201.
[http://dx.doi.org/10.1080/13814788.2017.1350645] [PMID: 28743214]
[13]
Gullón A, Sánchez Fuentes D, López-de-Sá E, et al. Use of oral anticoagulants in complex clinical situations with atrial fibrillation. Med Clin (Barc) 2018; 150(Suppl. 1): 8-24.
[PMID: 30502871]
[14]
Arnao V, Agnelli G, Paciaroni M. Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation. Intern Emerg Med 2015; 10(5): 555-60.
[http://dx.doi.org/10.1007/s11739-015-1226-4] [PMID: 25862436]
[15]
Alexopoulos D, Vlachakis P, Lekakis J. Triple antithrombotic therapy in atrial fibrillation patients undergoing PCI: A fading role. Cardiovasc Drugs Ther 2017; 31(3): 319-24.
[http://dx.doi.org/10.1007/s10557-017-6730-5] [PMID: 28643219]
[16]
Messori A, Fadda V, Gatto R, Maratea D, Trippoli S. New oral anticoagulants in acute coronary syndrome: is there any advantage over existing treatments? Int Cardiovasc Res J 2014; 8(3): 124-6.
[PMID: 25177676]
[17]
Ye Y, Xie H, Zeng Y, Zhao X, Tian Z, Zhang S. Optimal oral antithrombotic regimes for patients with acute coronary syndrome: A network meta-analysis. PLoS One 2014; 9(3)e90986
[http://dx.doi.org/10.1371/journal.pone.0090986] [PMID: 24614630]
[18]
Khan SU, Arshad A, Riaz IB, Talluri S, Nasir F, Kaluski E. Meta-analysis of the safety and efficacy of the oral anticoagulant agents (apixaban, rivaroxaban, dabigatran) in patients with acute coronary syndrome. Am J Cardiol 2018; 121(3): 301-7.
[http://dx.doi.org/10.1016/j.amjcard.2017.10.035] [PMID: 29195825]
[19]
Amsterdam EA, Wenger NK, Brindis RG, et al. AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64(24): 2645-87.
[http://dx.doi.org/10.1016/j.jacc.2014.09.016] [PMID: 25260718]
[20]
GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329(10): 673-82.
[http://dx.doi.org/10.1056/NEJM199309023291001] [PMID: 8204123]
[21]
Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13(11): 2119-26.
[http://dx.doi.org/10.1111/jth.13140] [PMID: 26764429]
[22]
Kupó P, Szakács Z, Solymár M, et al. Direct anticoagulants and risk of myocardial infarction, a multiple treatment network meta-analysis. Angiology 2020; 71(1): 27-37.
[http://dx.doi.org/10.1177/0003319719874255] [PMID: 31533437]
[23]
Fu L, Zhu W, Huang L, et al. Efficacy and safety of the use of non-vitamin k antagonist oral anticoagulants in patients with ischemic heart disease: A meta-analysis of phase III randomized trials. Am J Cardiovasc Drugs 2019; 19(1): 37-47.
[http://dx.doi.org/10.1007/s40256-018-0299-7] [PMID: 30182350]
[24]
Roule V, Ardouin P, Briet C, et al. Vitamin K antagonist vs direct oral anticoagulants with antiplatelet therapy in dual or triple therapy after percutaneous coronary intervention or acute coronary syndrome in atrial fibrillation: Meta-analysis of randomized controlled trials. Clin Cardiol 2019; 42(9): 839-46.
[http://dx.doi.org/10.1002/clc.23224] [PMID: 31290171]
[25]
Lopes RD, Hong H, Harskamp RE, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: A network meta-analysis of randomized controlled trials. JAMA Cardiol 2019; 4(8): 747-55.
[http://dx.doi.org/10.1001/jamacardio.2019.1880] [PMID: 31215979]
[26]
Chiarito M, Cao D, Cannata F, et al. Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: A systematic review and meta-analysis. JAMA Cardiol 2018; 3(3): 234-41.
[http://dx.doi.org/10.1001/jamacardio.2017.5306] [PMID: 29417147]
[27]
Oldgren J, Wallentin L, Alexander JH, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: A systematic review and meta-analysis. Eur Heart J 2013; 34(22): 1670-80.
[http://dx.doi.org/10.1093/eurheartj/eht049] [PMID: 23470494]
[28]
Komócsi A, Vorobcsuk A, Kehl D, Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: Systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172(20): 1537-45.
[http://dx.doi.org/10.1001/archinternmed.2012.4026] [PMID: 23007264]
[29]
Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006; 27(10): 1166-73.
[http://dx.doi.org/10.1093/eurheartj/ehi877] [PMID: 16621870]
[30]
Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008; 29(1): 21-30.
[http://dx.doi.org/10.1093/eurheartj/ehm545] [PMID: 18055486]
[31]
Cannon CP, Husted S, Harrington RA, et al. DISPERSE-2 Investigators.Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50(19): 1844-51.
[http://dx.doi.org/10.1016/j.jacc.2007.07.053] [PMID: 17980250]
[32]
Frere C, Cuisset T, Morange PE, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008; 101(8): 1088-93.
[http://dx.doi.org/10.1016/j.amjcard.2007.11.065] [PMID: 18394438]
[33]
Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299(5): 532-9.
[http://dx.doi.org/10.1001/jama.299.5.532] [PMID: 18252883]
[34]
Wallentin L, Wilcox RG, Weaver WD, et al. ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomised controlled trial. Lancet 2003; 362(9386): 789-97.
[http://dx.doi.org/10.1016/S0140-6736(03)14287-0] [PMID: 13678873]
[35]
Steg PG, Mehta SR, Jukema JW, et al. RUBY-1 Investigators. RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011; 32(20): 2541-54..
[http://dx.doi.org/10.1093/eurheartj/ehr334] [PMID: 21878434]

Rights & Permissions Print Cite
Article Metrics
27
1
© 2024 Bentham Science Publishers | Privacy Policy